Details of the Drug

General Information of Drug (ID: DM45HT6)

Drug Name
Glofitamab
Synonyms RG6062
Indication
Disease Entry ICD 11 Status REF
Diffuse large B-cell lymphoma 2A81 Approved [1]
Follicular lymphoma 2A80 Phase 1 [2]
Drug Type
Antibody
Cross-matching ID
TTD ID
DKF7G0
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN Modulator [3]
T-cell surface glycoprotein CD3 (CD3) TTUN7MC NOUNIPROTAC Modulator [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761309
2 ClinicalTrials.gov (NCT04246086) A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide, Glofitamab + Lenalidomide, and Glofitamab + Lenalidomide + Obinutuzumab in Participants With Relapsed or Refractory Follicular Lymphoma. U.S. National Institutes of Health.
3 Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021 Jun 20;39(18):1959-1970.